What smart money is saying about NewAmsterdam Pharma
NAMS
No fund has written a full thesis on NewAmsterdam Pharma in our archive, but 1 fund letter reports a position in it, most recently Timessquare US Small Cap Growth Strategy in September 2025.
Get an email when a fund buys, sells or pitches it
1
Reported positions
0
Bought
0
Sold
1
Letter
Position history
Every position in NewAmsterdam Pharma on record in the archive was reported in Q3 2025, across 1 fund letter, with no move described.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2025 | 1 | 0 | 0 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 1 position
- September 2025
“Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. One example was NewAmsterdam Pharma, a biopharma developer of cholesterol inhibitors for cardiovascular diseases.”
NewAmsterdam Pharma
Read the letters behind these NewAmsterdam Pharma positions
Every quote above comes from a fund letter in our archive. Get unlimited access to the letters themselves, and to Warren AI, which reads all of them for you.
View plans→Share this ledger